The serendipitous discovery of cisplatin opened the door to platinum-based cancer therapy. Even in the era of immunotherapy and precision medicine, platinum compounds are still the mainstay of chemotherapy regimens for various cancers. However, platinum compounds suffer from drug resistance, off-target problems, and various side effects including nephrotoxicity, myelosuppression, ototoxicity, pulmonary toxicity, and neurotoxicity. The emergence of luminescent metal complexes offers tremendous opportunities to address the issues of platinum-based cancer therapy. Luminescent metal complexes, especially noble metal complexes (iridium, ruthenium, gold, osmium, etc.) and lanthanide complexes (europium, neodymium, ytterbium, etc) have the advantage of desirable optical properties and tunable therapeutic effects. These complexes have been developed for targeted cancer therapy, photodynamic therapy, combination cancer therapy with other immunotherapy or targeted therapy, targeted delivery, and theranostics. Considerable efforts in this area have resulted in the development of clinical candidates for cancer diagnosis and therapy such as TLD1433, representing the next generation of metallodrugs.
This research topic will focus on progress and challenges in the development of luminescent transition metal complexes and lanthanide complexes for cancer imaging and therapy. We aim to provide the latest insights on the emerging applications of luminescent transition metal complexes and lanthanide complexes in anticancer therapy and diagnostics, and provide future directions for accelerating the clinical development of luminescent metal-based probes and metallodrugs.
We welcome submissions covering, but not limited to, the following themes:
• Development of noble metal complexes probes for cancer biomarkers and the tumor microenvironment imaging
• Design and development of new noble metal complexes for efficient photodynamic therapy
• Exploration of luminescent transition complexes for cancer theranostics in vitro and in vivo
• Design and development of luminescent lanthanide complexes for cancer bioimaging
• Mechanism of noble metal complexes and lanthanide complexes on imaging sensing type, interaction modes with biomolecules and the effect on signal pathways
• Clinical transition studies of transition metal complexes and lanthanide complexes in cancer diagnosis and therapy
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
The serendipitous discovery of cisplatin opened the door to platinum-based cancer therapy. Even in the era of immunotherapy and precision medicine, platinum compounds are still the mainstay of chemotherapy regimens for various cancers. However, platinum compounds suffer from drug resistance, off-target problems, and various side effects including nephrotoxicity, myelosuppression, ototoxicity, pulmonary toxicity, and neurotoxicity. The emergence of luminescent metal complexes offers tremendous opportunities to address the issues of platinum-based cancer therapy. Luminescent metal complexes, especially noble metal complexes (iridium, ruthenium, gold, osmium, etc.) and lanthanide complexes (europium, neodymium, ytterbium, etc) have the advantage of desirable optical properties and tunable therapeutic effects. These complexes have been developed for targeted cancer therapy, photodynamic therapy, combination cancer therapy with other immunotherapy or targeted therapy, targeted delivery, and theranostics. Considerable efforts in this area have resulted in the development of clinical candidates for cancer diagnosis and therapy such as TLD1433, representing the next generation of metallodrugs.
This research topic will focus on progress and challenges in the development of luminescent transition metal complexes and lanthanide complexes for cancer imaging and therapy. We aim to provide the latest insights on the emerging applications of luminescent transition metal complexes and lanthanide complexes in anticancer therapy and diagnostics, and provide future directions for accelerating the clinical development of luminescent metal-based probes and metallodrugs.
We welcome submissions covering, but not limited to, the following themes:
• Development of noble metal complexes probes for cancer biomarkers and the tumor microenvironment imaging
• Design and development of new noble metal complexes for efficient photodynamic therapy
• Exploration of luminescent transition complexes for cancer theranostics in vitro and in vivo
• Design and development of luminescent lanthanide complexes for cancer bioimaging
• Mechanism of noble metal complexes and lanthanide complexes on imaging sensing type, interaction modes with biomolecules and the effect on signal pathways
• Clinical transition studies of transition metal complexes and lanthanide complexes in cancer diagnosis and therapy
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.